Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Grace reviewing NMC options

This article was originally published in The Gray Sheet

Executive Summary

Grace reviewing NMC options: W.R. Grace's newly elected president and CEO Albert Costello tells shareholders at Grace's May 10 annual meeting that the firm is weighing several alternatives for the divestiture of its National Medical Care dialysis unit. Last week, Grace received a $3.5 bil. acquisition offer for NMC from Constantine Hampers, a Grace executive VP and NMC's chairman and CEO ("The Gray Sheet" May 8, p. 14). "We are giving [Hampers'] proposal serious consideration and have retained the services of Merrill Lynch and First Boston to help us evaluate it," Costello told the stockholders in Boca Raton, Florida. Grace's board will "evaluate the Hampers proposal and other alternatives relating to NMC within approximately 30 to 60 days," the company said in a release...

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel